Literature DB >> 14996482

The role of iodine-123-labeled 15-(p-iodophenyl)-3R,S-methylpentadecanoic acid scintigraphy in the detection of local myocardial involvement of sarcoidosis.

Tatsuro Kaminaga1, Touru Takeshita, Teiyu Yamauchi, Hikaru Kawamura, Masami Yasuda.   

Abstract

PURPOSE: The purpose of this study is to examine the role of Iodine-123-labeled 15-(p-iodophenyl)-3R,S-methylpentadecanoic acid (BMIPP) scintigraphy in patients with cardiac sarcoidosis. METHODS AND MATERIALS: Study materials were six patients with pathologically proven cardiac sarcoidosis. BMIPP and resting Thallium-201 (201Tl) myocardial scintigraphy, echocardiography, were performed within 22 days in each patient.
RESULTS: Myocardium was divided into nine areas per one case. A total of 24 areas had involvement by sarcoidosis. A total of 18 areas with defects of BMIPP accumulation and 14 areas with defects of 201Tl accumulation were detected. A total of 12 areas were determined as showing reduced wall motion. The sensitivity, specificity, positive and negative predictive values of wall motion abnormality for the detection of myocardial involvement were 50%, 100%, 100% and 71%. The sensitivities of BMIPP and 201Tl scintigraphy for the detection of local myocardial involvement were 75% and 58%. The specificities of BMIPP and 201Tl scintigraphy were both 100%. The positive predictive values of BMIPP and 201Tl scintigraphy were both 100%. The negative predictive values of BMIPP and 201Tl scintigraphy were 83% and 75%.
CONCLUSION: BMIPP scintigraphy was more sensitive and had a higher negative predictive value compared to 201Tl scintigraphy and echocardiography for the detection of myocardial involvement of sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996482     DOI: 10.1016/j.ijcard.2003.05.012

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Shinichiro Kumita; Keiichiro Yoshinaga; Masao Miyagawa; Mitsuru Momose; Keisuke Kiso; Tokuo Kasai; Masanao Naya
Journal:  J Nucl Cardiol       Date:  2019-08       Impact factor: 5.952

Review 2.  Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disorders.

Authors:  Sandip Basu; Babak Saboury; Tom Werner; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

Review 3.  ¹⁸F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis.

Authors:  Hiroshi Ohira; Ichizo Tsujino; Keiichiro Yoshinaga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

Review 4.  Advanced imaging of cardiac sarcoidosis.

Authors:  Chadi Ayoub; Elena Pena; Hiroshi Ohira; Alexander Dick; Eugene Leung; Pablo B Nery; David Birnie; Rob S B Beanlands
Journal:  Curr Cardiol Rep       Date:  2015       Impact factor: 2.931

Review 5.  Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment.

Authors:  Joseph P Lynch; Jennifer Hwang; Jason Bradfield; Michael Fishbein; Kalyanam Shivkumar; Roderick Tung
Journal:  Semin Respir Crit Care Med       Date:  2014-07-09       Impact factor: 3.119

Review 6.  Idiopathic giant cell myocarditis and cardiac sarcoidosis.

Authors:  Lori A Blauwet; Leslie T Cooper
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.